Thus, they concluded that bone marrow‐derived MSCs and adipose‐derived MSCs are similarly effective at attenuating liver fibrosis.36 In contrast, Baligar et al demonstrated that bone marrow‐derived CD45+ MSCs had better anti‐fibrotic ability than adipose‐derived MSCs because they expressed higher levels of MMP‐9 and MMP‐13 and inhibited HSC proliferation more effectively.37 Most comparisons were conducted between bone marrow‐derived MSCs and other MSCs, while the optimal choice is still undetermined for treating liver fibrosis. The gene discussed is MMP9; the disease is Hepatic fibrosis.